Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States

Completed

Conditions studied: SARS-CoV-2

In brief

The goal of this study is to add to the ongoing active and passive safety signal detection through signal refinement and, if needed, evaluation of potential safety signals related to taking the SARS-CoV-2 mRNA-1273 vaccine.

Key facts

Study ID

NCT04958954

Run by

ModernaTX, Inc.

People needed

50000000

Starts

2021-07-07

Expected to finish

2023-06-30

Last updated by the study team

2023-07-17

Who can join

Age: any. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Included in a health plan covered by HealthVerity database
• Covered by a health plan during at least 1 period of interest (pre-COVID-19, active-COVID-19, and post-EUA periods), but not necessarily the full period.
• Demonstrate an AESI specified clean period of continuous baseline enrollment or activity before the period of interest (pre-COVID-19, active-COVID-19, and post-EUA periods) during which the participant is covered.

You may not qualify if…

• None

Where it is running

• Aetion Inc. — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.